Literature DB >> 11534659

Contemporaneous and successive mixed Plasmodium falciparum and Plasmodium vivax infections are associated with Ascaris lumbricoides: an immunomodulating effect?

M Nacher1, P Singhasivanon, F Gay, U Silachomroon, W Phumratanaprapin, S Looareesuwan.   

Abstract

Following an investigation suggesting a protective role for Ascaris against cerebral malaria, possibly through immunomodulation, we examined whether Ascaris had any impact on mixed Plasmodium falciparum and Plasmodium vivax infections. We studied a cross section of 928 patient files between 1991 and 1999. Forty patients had contemporaneous mixed infections and 40 patients had P. falciparum infections, followed by P. vivax infections. There was a significant association between Ascaris infection and risk of having both contemporaneous or successive mixed P. falciparum and P. vivax infections (adjusted odds ratios respectively 6 [2-18] P = 0.001 and 3.6 [1.2-11.1] P = 0.02). There was a positive linear trend between the burden of Ascaris and the risk of mixed infections P < 0.0001. These results suggested the possibility that pre-existing Ascaris infection may increase tolerance of the host to different Plasmodium spp., thus facilitating their coexistence.

Entities:  

Mesh:

Year:  2001        PMID: 11534659     DOI: 10.1645/0022-3395(2001)087[0912:CASMPF]2.0.CO;2

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  17 in total

1.  Impairment of protective immunity to blood-stage malaria by concurrent nematode infection.

Authors:  Zhong Su; Mariela Segura; Kenneth Morgan; J Concepcion Loredo-Osti; Mary M Stevenson
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 2.  Malaria and helminth interactions in humans: an epidemiological viewpoint.

Authors:  T W Mwangi; J M Bethony; S Brooker
Journal:  Ann Trop Med Parasitol       Date:  2006-10

3.  Concurrent helminthic infection protects schoolchildren with Plasmodium vivax from anemia.

Authors:  Gisely Cardoso Melo; Roberto Carlos Reyes-Lecca; Sheila Vitor-Silva; Wuelton Marcelo Monteiro; Marilaine Martins; Silvana Gomes Benzecry; Maria das Graças Costa Alecrim; Marcus Vinícius Guimarães Lacerda
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

Review 4.  Interactions between worm infections and malaria.

Authors:  Mathieu Nacher
Journal:  Clin Rev Allergy Immunol       Date:  2004-04       Impact factor: 8.667

5.  Plasmodium falciparum and helminth coinfection in a semi urban population of pregnant women in Uganda.

Authors:  Stephen D Hillier; Mark Booth; Lawrence Muhangi; Peter Nkurunziza; Macklyn Khihembo; Muhammad Kakande; Moses Sewankambo; Robert Kizindo; Moses Kizza; Moses Muwanga; Alison M Elliott
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

6.  Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control.

Authors:  Kevin C Kobylinski; Haoues Alout; Brian D Foy; Archie Clements; Poom Adisakwattana; Brett E Swierczewski; Jason H Richardson
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

Review 7.  Interactions between worms and malaria: good worms or bad worms?

Authors:  Mathieu Nacher
Journal:  Malar J       Date:  2011-09-12       Impact factor: 2.979

8.  Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria.

Authors:  Peter J Hotez; David H Molyneux; Alan Fenwick; Eric Ottesen; Sonia Ehrlich Sachs; Jeffrey D Sachs
Journal:  PLoS Med       Date:  2006-01       Impact factor: 11.069

9.  Helminth-infected patients with malaria: a low profile transmission hub?

Authors:  Mathieu Nacher
Journal:  Malar J       Date:  2012-11-15       Impact factor: 2.979

10.  Malaria and related outcomes in patients with intestinal helminths: a cross-sectional study.

Authors:  Abraham Degarege; Mengistu Legesse; Girmay Medhin; Abebe Animut; Berhanu Erko
Journal:  BMC Infect Dis       Date:  2012-11-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.